Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Investigators examine effectiveness of probiotics for cancer treatment

Investigators examine effectiveness of probiotics for cancer treatment

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Survivors of childhood leukemia and lymphoma are at greater risk of chronic fatigue: Study

Survivors of childhood leukemia and lymphoma are at greater risk of chronic fatigue: Study

Study links inherited variations in few genes to increased risk of pediatric leukemia

Study links inherited variations in few genes to increased risk of pediatric leukemia

St. Jude Children's Research Hospital receives patent for genetically modified human immune cells for caner therapy

St. Jude Children's Research Hospital receives patent for genetically modified human immune cells for caner therapy

Research: Decreased levels of vitamin D may influence smokers to develop tobacco-related cancer

Research: Decreased levels of vitamin D may influence smokers to develop tobacco-related cancer

Results from GTx's Phase 2 clinical trial of enobosarm published online

Results from GTx's Phase 2 clinical trial of enobosarm published online

Griffith University researchers discover critical weakness in leukaemic cells

Griffith University researchers discover critical weakness in leukaemic cells

Advanced gene sequencing test helps clinicians treat cancer

Advanced gene sequencing test helps clinicians treat cancer

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Targeting Mer receptors sensitize AML and ALL to chemotherapies

Targeting Mer receptors sensitize AML and ALL to chemotherapies

St. Jude Children's Research Hospital receives donation from Warren Sulmasy

St. Jude Children's Research Hospital receives donation from Warren Sulmasy

CALHM1 protein controls sense of taste, finds study

CALHM1 protein controls sense of taste, finds study

Fukushima report sheds light on future health risks

Fukushima report sheds light on future health risks

Media examine reaction to, potential implications of 'functional cure' of infant born with HIV

Media examine reaction to, potential implications of 'functional cure' of infant born with HIV

Stem cell transplantation could be delayed in acute myeloid leukemia

Stem cell transplantation could be delayed in acute myeloid leukemia

Anti-metabolic syndrome efforts needed for young ALL survivors

Anti-metabolic syndrome efforts needed for young ALL survivors

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Study finds how to shut down Bcl6 in diffuse large B-cell lymphoma

Study finds how to shut down Bcl6 in diffuse large B-cell lymphoma

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.